

Meeting Logistics

Item	Description
Date	January 10, 2022
Time	2:30 p.m. – 4:00 p.m.
Location	Call-in only
	Public call-in for listen only
Purpose/Focus	Health Research Advisory Committee Meeting – Public
Notetaker	Health Research Office Staff

Agenda

ID	Description	Owner	Time
1	Welcome, Introductions	Deputy Secretary Jared	2:30 pm –
		Shinabery	2:50 pm
2	Review and Approval of Meeting Minutes for 7/12/2021	Deputy Secretary Jared	2:50 pm –
	and 8/23/2021	Shinabery	3:10 pm
3	Review of the CURE Program and	Deputy Secretary Jared	3:10 pm –
	Updates 2020-2021 COVID-19 update	Shinabery	3:20 pm
4	Non-formula Funds Priority Language discussion 2021-	Deputy Secretary Jared	3:20 pm –
	2022	Shinabery	3:40 pm
5	Open Discussion	All attendees	3:40 pm –
	Open discussion		3:50 pm
6	Public Comments and Questions	Deputy Secretary Jared	3:50 pm –
	Fubile Comments and Questions	Shinabery	3:55 pm
7	Closing and Next Steps	Deputy Secretary Jared	3:55 pm –
		Shinabery	4:00 pm



	Treatti Research Advisory Committee				
ID	Description				
	Deputy Secretary Jared Shinabery, introduced himself, and members and DOH staff introduced themselves. Public attendees introduced themselves. Deputy Secretary Jared Shinabery, reviewed Agenda. Attendees were made aware that meeting minutes were being taken by a stenographer to accurately reflect the actions and recommendations made by the Committee.				
1	HRAC Members in Attendance Doh Members Dwight Davis, MD - Karen Wolk Feinstein, PhD Anantha Shekhar, MD PhD Michael Parmacek, MD Michele Masucci, PhD HRAC Members Jared Shinabery Will Cramer Galen Graham Stephanie Landis Pam Brown				
	HRAC Members not in Attendance Donna Gentile O'Donnell, PhD Pat Vance, retired PA state Senator Peter Tombros, MBA Michael lane Michael Smith Chick O'Rourke				
2	Deputy Secretary Shinabery introduced the review and approval of meeting minutes from November 15, 2021, as the first order of business. Dr. Davis moved for approval of the minutes seconded by Dr. Parmacek. With no corrections or discussion requested, a vote on the minutes passed unanimously and the November 15, 2021 minutes were approved.				



Deputy Secretary Jared introduced Will Cramer to provide program updates.

■ COVID-19 RFA UPDATE

- The final amount available for the COVID-19 priority was \$11,562,114.
- There were three awardees
- Each awardee will receive less than \$4M.
- Awardees and grant amounts are as follows:

Penn State University \$3,963,531
The Children's Hospital of Phila \$3,963,531
The University of Pennsylvania \$3,635,052

LEGISLATIVE ADDITIONS

- o 5 w/HRO
- 9 w/Procurement or Fully Executed

■ SPINAL CORD

6 w/Procurement or Fully Executed

■ FORMULA

- 24 w/ Procurement or Fully Executed
- 3 w/HRO\
- o 2021 RFA
 - TENTATIVE POSTING LATE JANUARY
 - Applications Due Late March
 - Application Review / Revision April
 - FULLY EXECUTED DOCUMENTS BY JUNE 30™

■ Non-Formula — Target March for RFA Release

- O 2021 PEDIATRIC CANCER PRIORITY LANGUAGE APPROVED / RFA DRAFT TBI
- 2021 Capital and Equipment Priority Language Approved / RFA Draft TBI

PEDIATRIC CANCER

6 APPLICATIONS W/ HRO

Pediatric Cancer applications were associated with Donation grants rather than non-Formula priority grants.

■ FORMULA FUND PRIORITIES

- As a reminder, the research priorities for the formula funds are clinical, health services, and/or biomedical research as defined by the Act.
- A total of \$34,971,400 has been tentatively allocated for Formula Grant awards.
- The Request for Application (RFA) progressed through the Procurement Office and Office of Legal Counselearlier today.
- After posting of the RFA, Health Research Office staff will announce an opportunity for grantees to submit questions and host a webinar to review respective answers.

3



Deputy Secretary Jared Shinabery requested Mr. Cramer provide an update on the NF language since last meeting:

■ NON-FORMULA FUND PRIORITIES

- During our November 15, 2021 meeting, we reviewed Act 24 of 2021 defunding the 2021-2022 Biology of Aging priority and funding pediatric cancer research and capital and equipment for biotechnology research.
- Similarly, the Committee discussed the proposed language for the pediatric cancer priority and a motion was made and was passed to approve the combination RFA language presented by Dr. Shekhar pending Legal Office review and approval.
- The Legal Office reviewed and approved pediatric cancer priority language as written on December 15, 2021.
- The Committee discussed the proposed language for the capital and equipment for biotechnology research priority and a motion was made and was passed to approve the proposed language pending Legal Office review and approval.
- The Legal Office reviewed and approved the capital and equipment priority language as written on December 15, 2021. There was a question brought up in the last meeting about human embryonic stem cells. Though the research priority provided by the committee does not mention human embryonic stem cells, we nonetheless require that all applicants affirm that they will comply with the law as it pertains to human embryonic stem cells. This is standard practice for our research grants. The required form, titled "Certification for the Protection of Human Subjects and Regarding the Use of Human Embryonic Stem Cell Research" was provided to the committee members via email last week.
- We are in the process of developing the RFA. It will be approximately 3-4 months before that is complete and the RFA document can be posted.

NON-FORMULA USE OF FUND FOLLOW-UP

 There was an outstanding question from the November meeting about what percentage of non-formula funds can be spent on infrastructure.
 Section 907 of Act 77 limits non-formula funds to maximum of 50% going to infrastructure.

4



	Treatm Research Advisory Committee
	Open Discussion
5	 Dr. Shekhar questioned the timeframe for Formula vs. non-Formula grant release and milestones to get back on tract with a normal schedule
	• Mr. Cramer reviewed tentative plans for release of the Spinal Cord RFA and Formula RFA. The group agreed the timeline was aggressive, but the goal was to get grants out by the end of June 2021.
	 Non-formula RFA documents are under development as language was just approved.
	 Dr. Davis indicated that the agenda for the April 4th meeting should be how the committee can maintain good science moving forward.
	 Jared Shinabery suggested these topics be discussed in an Executive Meeting prior to the April 4th public meeting. A Doodle poll will be generated to schedule an Executive Meeting.
	Deputy Secretary Jared Shinabery opened the floor for public comments and questions.
	 Maggie McDonald questioned the appropriate route to get answers to day-to-day grant
6	questions.
	Grantees should email the RA_Health Research resource account.
	 Priority is on getting new grants out. Amendments, budget revisions, no cost extensions and
	other adjustments to existing grants must come secondary.
	Deputy Secretary Jared Shinabery expressed appreciation for the Committee's hard work on this
7	RFA and discussion. He requested a motion to adjourn. <i>Dr. Parmacek</i> moved to accept the motion.
,	Dr. Davis second. No discussion. No opposition or abstentions. The motion passed unanimously.
	Meeting was adjourned at 3:17 PM.